Application of PRP in Chloasma: A Meta-Analysis and Systematic Review

Table 2

Demographic and clinical characteristics of participants.

Study	Gender (M/F)	Grouping	Fitzpatrick skin type	Depth	Distribution	Baseline score	Duration of illness	Triggering factor
Hofny et al. 2019 [3]	4/19	A: microneedling with Dermapen	Types III: 7	Epidermal: 18	Malar: 1	MASI:A: 6.13 ± 2.73	1–3 years: 12 patients	Sun exposure:16 Hormonal Contraception: 3
		B: microinjections using mesoneedles	Types IV: 16	Mixed: 5	Centrofacial: 22	B: 5.73 ± 2.77 mMASI:5.71 ± 2.56	˃3 years: 11 patients	Pregnancy: 4
Sirithanabadeekul et al. 2020 [4]	0/10	A: intradermal PRP	Types III: 2	Mixed: 10	—	A: 4.92 ± 0.96	—	—
		B: intradermal normal saline	types V: 8			B: 4.98 ± 0.86
Mumtaz et al. 2021 [1]	35/29	A: intradermal PRP	—	—	—	A: 29.84 ± 5.14	A: 24.63 ± 9.87 months	—
		B: intradermal tranexamic				B: 29.56 ± 4.39	B: 23.94 ± 8.93 months
Adel et al. 2021 [18]	0/20	A: IPL	Types II: 3	Epidermal: 6	Centrofacial: 19	MASI:16.3 ± 7.7 mMASI:	2 months-18 years	Sun exposure: 13
		B: PRP-IPL	Types III: 9	Mixed: 14	Malar: 1	A:19 ± 6.4B: 19.8 ± 5.8		Pregnancy:0
			types V: 8
Gamea et al. 2020 [19]	0/40	A: topical 5%	Types III (A: 11 B:12)	Epidermal: (A:12 B:8)	—	mMASI:	A:12–72 months	—
		Tranexamic acid + PRP	Types IV (A: 9 B:8)	Mixed: (A:8 B:12)		A: 12.1 ± 2.9	B: 18–80 months
		B: topical 5% tranexamic acid				B: 11.7 ± 2.98
Faiz and Meng 2018 [20]	12/3	—	Types III: 4	—	—	MASI:	—	—
			Types IV: 11			15.71 ± 6.81
Tuknayat et al. 2021 [2]	36/4	—	Types IV and V	Epidermal: 29	Malar: 8	mMASI:13.7	—	—
				Mixed: 11	Centrofacial: 31
					Mandibular: 1

PRP: platelet-rich plasma; IPL: intense pulse light; MASI: melasma area severity index; mMASI: modified melasma area severity index.